Clinical Trials
52 trialsA Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
Electra Therapeutics Inc.
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
M.D. Anderson Cancer Center
A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)
Memorial Sloan Kettering Cancer Center
Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
Lantern Pharma Inc.
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
KinLET
ITM Solucin GmbH
Indocyanine Green (ICG) Guided Tumor Resection
St. Jude Children's Research Hospital
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
CD4CAR for CD4+ Leukemia and Lymphoma
Indiana University
Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies
Jabez Bioscience, Inc
REALIZE
University of Oklahoma
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics, Inc.
U96-CAR-T-Cells For R/R B-ALL
The First Affiliated Hospital of Soochow University
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Medical College of Wisconsin
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
Treeline Biosciences, Inc.
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics, Inc.
GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL
The First Affiliated Hospital of Xiamen University
GRALE
Baylor College of Medicine
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
Dana-Farber Cancer Institute
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
FBD Biologics Limited
POTENTIAL-M
NOBO Medicine
Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)
City of Hope Medical Center
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
St. Jude Children's Research Hospital
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
UNC Lineberger Comprehensive Cancer Center
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Umoja Biopharma
24CT015
Children's Hospital of Philadelphia
ON-5001
OncoNano Medicine, Inc.
S101MRD
Peking University People's Hospital
VIPER101
Vittoria Biotherapeutics
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
Case Comprehensive Cancer Center
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
Treeline Biosciences, Inc.
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Iksuda Therapeutics Ltd.
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
SciTech Development, Inc.
BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
iCell Gene Therapeutics
A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma(Keyplus-001)
L & L Bio Co., Ltd., Ningbo, China
uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
Institute of Hematology & Blood Diseases Hospital, China
APOLLO
Marker Therapeutics, Inc.
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Stanford University
A Phase I Dose Finding Study of MB-CART2219.1
University Hospital Tuebingen
CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
Institute of Hematology & Blood Diseases Hospital, China
RELY-30
Baylor College of Medicine
A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
ADC Therapeutics S.A.
Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL
University Health Network, Toronto
A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer
Fox Chase Cancer Center
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Caribou Biosciences, Inc.
First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma
EpimAb Biotherapeutics (Suzhou)Co., Ltd.
A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
Betta Pharmaceuticals Co., Ltd.
Intratumoral CAN2109 in Subjects With Solid Tumors
Canwell Biotech Limited
Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors
Taivex Therapeutics Corporation
A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.